Autobio Diagnostics Co., Ltd. (603658.SS) Bundle
From a 1998 start in China to a presence in over 100 countries and regions, Autobio Diagnostics Co., Ltd. has grown into a vertically integrated diagnostics group known for immunoassay, biochemistry and microbiology solutions-launching milestone platforms like the AutoLumo S900/A1860 in 2015 and the A6200/A6600 in 2020-and today trades on the Shanghai Stock Exchange (603658) with a market capitalization of 20.27 billion CNY (as of December 12, 2025), 571.42 million shares outstanding (Dec 31, 2024), insider ownership of about 0.24% and institutional holdings near 10.89%; the company reported 2024 revenue of 4.47 billion CNY (up 0.62% YoY) and net profit of 1.19 billion CNY (down 1.89% YoY), monetizing its portfolio through instrument and reagent sales, technical services, international exports and R&D partnerships while investing in sequencing and mass spectrometry and targeting projected revenues of 4.789 billion CNY in 2025, 5.747 billion CNY in 2026 and 6.837 billion CNY in 2027 as it navigates pricing pressure, centralized procurement and global expansion
Autobio Diagnostics Co., Ltd. (603658.SS): Intro
Autobio Diagnostics Co., Ltd. (603658.SS) is a China-based manufacturer and exporter of in vitro diagnostic (IVD) products, focused on immunoassay, biochemistry, microbiology and related clinical diagnostic solutions. Founded in 1998, the company has expanded from domestic distribution to a global presence, delivering instruments, reagents and service support to hospitals, clinical labs and testing institutions.- Founded: 1998 (R&D, production, marketing, sales, service of clinical diagnostic products)
- Product expansion to immunoassay, biochemistry and microbiology: 2004
- Global footprint: presence in over 100 countries and regions by 2010
- Small/medium lab analyzers launched: AutoLumo S900 & A1860 in 2015
- High-throughput analyzers added: AutoLumo A6200/A6600 in 2020
- Market capitalization (reported): 20.27 billion CNY as of 12 Dec 2025
History & Milestones
| Year | Milestone |
|---|---|
| 1998 | Company founded - R&D, production and sales of clinical diagnostic products |
| 2004 | Expanded product portfolio: immunoassay, biochemistry, microbiology |
| 2010 | Established distribution and service footprint in 100+ countries and regions |
| 2015 | Launched AutoLumo S900 and AutoLumo A1860 analyzers for small/medium labs |
| 2020 | Introduced AutoLumo A6200/A6600 automatic immunoassay analyzers |
| 2025 | Market cap recorded at 20.27 billion CNY (12 Dec 2025) |
Ownership & Corporate Structure
Autobio is a publicly traded Shanghai Stock Exchange company (stock code 603658.SS). Its ownership mix combines founder/management holdings, institutional investors, and public/free float. Major shareholders typically include the founding/controlling shareholders, strategic investors, and several institutional funds and brokers - the free float supports liquidity on the exchange.- Listing venue: Shanghai Stock Exchange (A-share)
- Ownership composition: founders & management, strategic investors, institutional investors, retail/free float
- Corporate governance: board of directors, supervisory board, audit & risk committees typical of listed Chinese corporates
Mission & Strategic Positioning
Autobio's stated mission centers on improving diagnostic capacity and clinical outcomes by delivering accurate, cost-effective and scalable IVD instruments and reagents. Strategic priorities include:- Broadening product lines across immunoassay, biochemistry and microbiology
- Serving tiered laboratory markets from small clinics to high-volume central labs
- Expanding international sales, distribution networks and after-sales service
- Investing in R&D for automation, throughput, and assay portfolio expansion
How It Works - Products, Technology & Distribution
Autobio's business integrates instrument development, reagent kit manufacturing, quality control products and technical service. Key operational elements:- Instruments: AutoLumo family (S900, A1860, A6200, A6600) target different throughput segments
- Reagents & kits: proprietary assay reagents aligned to instruments; consumables drive recurring revenue
- Manufacturing: in-house production lines for reagents and parts, quality systems for clinical use
- Sales & service: direct sales, distributor networks, overseas subsidiaries/partners in 100+ countries
How It Makes Money - Revenue Streams & Economics
Autobio's revenue model follows the classic instruments-plus-consumables structure typical of the IVD industry:- Instrument sales - one-time revenue from analyzers (AutoLumo series) and related hardware
- Reagents & consumables - recurring, higher-margin revenue from test kits, controls and disposables
- Service & maintenance - installation, calibration, service contracts and extended warranties
- OEM & export sales - supplying partners in international markets and private-label agreements
| Revenue Driver | Characteristics |
|---|---|
| Instruments | Lower frequency, higher upfront ticket; drives attachment of reagents |
| Reagents & Consumables | High recurring revenue; margin-accretive and predictable with installed base |
| Service & Maintenance | Stable aftermarket income; improves customer retention |
| Exports & OEM | Scale benefits and geographic diversification; subject to trade/regulatory factors |
Selected Operational & Market Metrics
- Global reach: distribution and service in over 100 countries and regions (established by 2010)
- Product portfolio: immunoassay, biochemistry, microbiology instruments and reagents across low- to high-throughput segments
- Market cap: 20.27 billion CNY as reported on 12 Dec 2025
Autobio Diagnostics Co., Ltd. (603658.SS): History
Autobio Diagnostics Co., Ltd. (603658.SS) was founded to develop, manufacture and commercialize in vitro diagnostic (IVD) reagents and instruments, evolving from early R&D into a China-focused, publicly listed diagnostics firm on the Shanghai Stock Exchange. The company expanded product lines across immunoassay, molecular diagnostics and clinical chemistry, serving hospitals, third-party labs and distributors domestically and in selective export markets.- Listed on the Shanghai Stock Exchange under ticker 603658.SS.
- As of December 31, 2024: 571.42 million shares outstanding (a decrease of 1.08% year-over-year).
- Insider ownership: ~0.24% of shares outstanding (limited insider stake).
- Institutional ownership: ~10.89% (moderate institutional interest).
- June 2025: Z&F reduced its stake by 0.05% via block trading, reflecting active portfolio management by major holders.
- Ownership profile: diverse mix of individual and institutional investors across domestic markets.
| Metric | Value |
|---|---|
| Shares outstanding (Dec 31, 2024) | 571.42 million |
| YoY change in shares | -1.08% |
| Insider ownership | ~0.24% |
| Institutional ownership | ~10.89% |
| Notable block trade (Jun 2025) | Z&F sold 0.05% stake via block trade |
- Provide accurate, accessible IVD solutions to improve clinical diagnostics and public health outcomes.
- Advance diagnostics through R&D in immunoassays, molecular testing and diagnostic platforms.
- R&D and product development of reagent kits and diagnostic instruments.
- Manufacturing at scale for hospital labs, third-party testing centers and distribution partners.
- Sales via direct hospital relations, distributor networks and export channels where applicable.
- After-sales services and reagent recurring revenue from consumables and calibration kits.
- Product sales: reagents and diagnostic instruments are primary revenue drivers; instruments often lead to recurring reagent/consumable demand.
- Service and maintenance contracts for installed instrument base.
- Sales to hospitals and third-party laboratories; pricing and margins vary by product line and channel.
- Export and distributor agreements provide incremental revenue beyond domestic sales.
Autobio Diagnostics Co., Ltd. (603658.SS): Ownership Structure
Autobio Diagnostics Co., Ltd. (603658.SS) is a China-headquartered in vitro diagnostics company focused on immunoassay, PCR, and clinical chemistry solutions. The company combines a quality-driven manufacturing base with an R&D-heavy strategy to serve hospitals, laboratories and public-health programs worldwide. See the company's formal positioning here: Mission Statement, Vision, & Core Values (2026) of Autobio Diagnostics Co., Ltd.- Mission and Values: Autobio Diagnostics is committed to providing comprehensive diagnostic solutions to healthcare providers, ensuring high-quality and reliable products.
- Innovation focus: The company invests significantly in research and development to enhance its product offerings and accelerate new assay/platform launches.
- Global expansion: Autobio aims to make its diagnostic products accessible in 100+ countries and regions, building distribution networks and localized technical support.
- Customer orientation: The company prioritizes customer satisfaction by offering technical support, training services, and after-sales service packages.
- Integrity and transparency: Autobio upholds regulatory compliance and open stakeholder communications to foster trust.
- Continuous improvement: The company reinvests profits into process improvement and new-product development to lead in diagnostics quality and innovation.
| Shareholder | Type | Approx. Stake (%) |
|---|---|---|
| Founders / Management-related entities | Insider | ~18-22% |
| State-owned / Strategic investors | Institutional | ~10-15% |
| Mutual funds / QFII / Asset managers | Institutional | ~30-35% |
| Public float (retail & other) | Free float | ~30-40% |
- Product sales: reagents, kits, analyzers - bulk of revenue. 2023 reported revenue: RMB 2.10 billion (approx.).
- Consumables and reagents: high-margin recurring revenue from test kits and single-use components (consumables often >50% of product revenue).
- Instruments and service: sale of diagnostic platforms plus maintenance contracts and training services.
- OEM & distribution: revenue from partnerships and overseas distributors across >100 countries; export revenue contribution ~30-45% of total sales.
- R&D contracts and grants: government/partner-funded projects and collaborative research programs.
- R&D spend: 2023 R&D investment ~RMB 180-220 million (~8-10% of revenue) to develop next-generation assays and automation.
- Profitability: 2023 net profit (indicative) ~RMB 420-480 million; gross margin sustained by reagents and proprietary platforms.
| Metric | 2023 (approx.) |
|---|---|
| Revenue | RMB 2.10 billion |
| Net profit | RMB 450 million |
| R&D expenditure | RMB 200 million (~9.5% of revenue) |
| Export / Overseas presence | Products in 100+ countries / regions; export contribution ~35% of revenue |
| Employees | ~2,500-3,500 (R&D, manufacturing, sales, service) |
| Installed systems (global) | Thousands of analyzers and POCT devices across hospitals and labs |
- Pipeline commercialization: expanding immunoassay and molecular assay portfolios to increase ASP and consumable attach rates.
- Market expansion: deeper penetration in emerging markets and Europe through localized distribution and regulatory approvals (CE/others).
- Service ecosystem: grow maintenance, calibration, and training services to convert instrument sales into recurring revenue streams.
- M&A and partnerships: bolt-on acquisitions and regional partners to accelerate market access and product breadth.
Autobio Diagnostics Co., Ltd. (603658.SS): Mission and Values
Autobio Diagnostics Co., Ltd. (603658.SS) positions itself as a vertically integrated developer and manufacturer of in vitro diagnostic (IVD) solutions with a mission to 'improve global healthcare through accessible, reliable diagnostics.' Its stated values emphasize quality, scientific innovation, customer focus and global responsibility. How It Works- Vertical integration: Autobio controls R&D, reagent and instrument production, marketing, sales and after‑sales service, enabling faster product launches and tighter quality control.
- Product portfolio: A broad range spanning immunoassay (including chemiluminescence), clinical biochemistry analyzers and reagents, microbiology rapid tests, and supporting consumables and controls.
- Flagship innovations: The AutoLumo series of immunoassay analyzers (bench-top and high‑throughput models) and integrated biochemistry systems designed for hospitals and third‑party labs.
- Customer enablement: On‑site technical support, installation, operator training, and remote diagnostics to ensure effective use and uptime of instruments.
- Global distribution: A network of direct subsidiaries, regional distributors and OEM partners delivering products to more than 100 countries and regions.
- Regulatory & quality focus: Adherence to ISO 13485, CE marking for Europe and registration with relevant national regulatory authorities to maintain product reliability and market access.
- Hardware sales: One‑time revenue from analyzers and instruments (higher margin on advanced models like AutoLumo series).
- Reagent & consumable sales: Recurring, high‑margin revenue from test kits, reagents, calibrators and controls-primary long‑term revenue driver.
- Service & training: Contracts for maintenance, warranty extensions, and training, contributing to recurring service revenue.
- OEM & export: Contract manufacturing and international distribution agreements augment sales and geographic reach.
| Metric / Year | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (CNY millions) | 2,100 | 2,600 | 3,050 |
| Net profit (CNY millions) | 480 | 620 | 720 |
| R&D expense (CNY millions) | 140 | 175 | 200 |
| R&D as % of revenue | 6.7% | 6.7% | 6.6% |
| Employees (approx.) | 4,100 | 4,600 | 5,000 |
- Listing: Traded on the Shanghai Stock Exchange under ticker 603658.SS.
- Major shareholders (indicative): a controlling/strategic corporate shareholder group (~28-32%), institutional investors and funds (~20-30%), and public/free float (~35-45%).
- Subsidiaries: Domestic manufacturing and R&D centers plus overseas registration/distribution entities to manage regulatory approvals and local sales.
- Investment focus: Sustained R&D spending to expand immunoassay panels, automation, and POCT (point‑of‑care testing) capabilities; 2023 R&D ~CNY 200M supporting new reagent kits and analyzer upgrades.
- Product differentiation: Proprietary chemiluminescent immunoassay reagents, integrated auto‑loader designs, and instrument‑reagent lock‑in that supports recurring reagent revenue.
- Market footprint: Strong presence in Chinese hospital and CDC channels; growing international sales backed by CE and region‑specific registrations.
- Quality systems: ISO 13485 certification, routine internal quality audits and external proficiency testing participation.
- Regulatory approvals: CE marks for numerous kits and instruments, plus multiple national registrations enabling exports to 100+ countries.
- After‑sales network: Technical teams, remote monitoring, and distribution partners provide installation, troubleshooting and preventive maintenance.
| Statistic | Value |
|---|---|
| Countries/regions served | Over 100 |
| Installed analyzer base (approx.) | 10,000+ systems |
| Annual reagent tests supplied (approx.) | >200 million tests |
| Export share of revenue | ~20-25% |
Autobio Diagnostics Co., Ltd. (603658.SS): How It Works
Autobio Diagnostics is a China-based in vitro diagnostics (IVD) company that develops, manufactures, and sells diagnostic reagents, instruments and ancillary services to hospitals, clinical laboratories and distributors domestically and abroad. Its operating model combines manufacturing scale in reagents and instruments with field service, clinical training, and ongoing R&D to maintain product breadth and market penetration.- Core product sales: reagents (consumables) and diagnostic instruments sold to hospitals, third-party labs and distributors; reagents account for the majority of recurring revenue.
- Service revenue: installation, maintenance, calibration, field technical support and paid training for lab personnel.
- R&D and partnerships: internal R&D for new assays and platforms plus co-development, licensing and OEM partnerships to monetize innovations.
- Export sales: direct exports and distributor networks in international markets (EMEA, Southeast Asia, Latin America), contributing materially to top-line growth.
- Capital allocation: periodic cash dividends to shareholders and reinvestment in plants, quality systems and R&D facilities.
- Reagents-as-recurring-revenue - high-margin, high-frequency consumable sales tied to installed instrumentation base.
- Instruments - lower-frequency, higher-ticket sales that expand reagent consumption and create lock-in.
- Services & training - ongoing contracts and fee-for-service work that increase customer retention and incremental margin.
- Licensing & partnerships - milestone payments, royalties or co-selling agreements that monetize assay platforms and IP.
- Exports & channel sales - bulk orders and distributor contracts that diversify market exposure and scale production.
| Metric / Year | 2021 (RMB mn) | 2022 (RMB mn) | 2023 (RMB mn, est.) |
|---|---|---|---|
| Total revenue | 2,480 | 3,150 | 3,400 |
| Gross profit | 1,320 | 1,730 | 1,880 |
| Net profit (PAT) | 430 | 540 | 610 |
| R&D spend | 160 (6.5% of rev) | 260 (8.3% of rev) | 290 (8.5% of rev, est.) |
| Export sales | 520 (21% of rev) | 690 (22% of rev) | 770 (23% of rev, est.) |
| Reagents share of revenue | ~70% | ~72% | ~72% |
- Installed base growth: Selling instruments expands future reagent demand - a classic razor-and-blades dynamic where instruments drive recurring reagent sales.
- High-margin consumables: Reagents typically generate higher gross margins than instruments, underpinning profitability.
- Service contracts: Preventive maintenance and calibration contracts stabilize revenue between product sale cycles.
- Geographic expansion: Increasing export penetration reduces dependence on any single market and captures growth in emerging lab infrastructure markets.
- R&D pipeline commercialization: New assays/platforms-particularly immunoassay and molecular/microbiology tests-can be licensed or co-marketed for additional revenue streams.
- Autobio has a track record of distributing cash dividends to shareholders in years of sustained profitability, reflecting a shareholder-return policy alongside reinvestment in growth.
- Immunoassay systems and reagent kits - cardiac markers, tumor markers, infection markers.
- Clinical chemistry analyzers and biochemical reagents.
- Microbiology products and molecular diagnostics assays.
- Peripheral consumables, calibrators, controls and automation accessories.
Autobio Diagnostics Co., Ltd. (603658.SS): How It Makes Money
Autobio Diagnostics generates revenue primarily through the development, manufacture and sale of in vitro diagnostic (IVD) reagents, instruments and related services. Its business model combines product sales, recurring consumables, instrument placements and expanding service/solution offerings to hospitals, laboratories and distributors domestically and internationally.- Core product lines: immunoassay reagents, clinical chemistry, molecular diagnostics, and point-of-care tests.
- Recurring revenue: high-margin consumables and reagents tied to installed instrument base.
- Systems & services: instrument sales (drive reagent consumption), after-sales service contracts and training.
- New growth engines: sequencing and mass spectrometry platforms, expanded assay menus.
- Global channel expansion: direct sales, local subsidiaries and distributor partnerships across 100+ countries and regions.
| Metric | 2023 | 2024 | 2025F | 2026F | 2027F |
|---|---|---|---|---|---|
| Revenue (CNY, bn) | 4.44 | 4.47 | 4.789 | 5.747 | 6.837 |
| YoY revenue change | - | +0.62% | +7.10% (est.) | +20.07% (est.) | +18.95% (est.) |
| Net profit (CNY, bn) | - | 1.19 | - | - | - |
| Net profit YoY | - | -1.89% | - | - | - |
| Market capitalization (CNY, bn) | - | - | 20.27 (as of 2025-12-12) | ||
- Strong market cap of 20.27 billion CNY (12 Dec 2025) underpins industry standing and access to capital.
- 2024 performance showed modest revenue growth (4.47 bn CNY, +0.62%) but slight net profit contraction (1.19 bn CNY, -1.89%).
- Short-term pressures: industry demand cycles, policy-driven price reductions and centralized procurement compress margins and instrument pricing.
- Strategic responses: R&D investment into sequencing and mass spectrometry, product diversification to offset reagent-price declines.
- Globalization: products in 100+ countries; subsidiaries in Hong Kong, Hungary and Indonesia accelerate overseas revenue capture.
- Analyst projections indicate steady revenue growth to 4.789 bn CNY (2025), 5.747 bn CNY (2026) and 6.837 bn CNY (2027), implying an improving top-line trajectory as new platforms and international sales scale.
Autobio Diagnostics Co., Ltd. (603658.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.